[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Measles Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 48 pages | ID: M4D7E97A2AB1EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Measles Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Measles - Drugs In Development, 2022, provides an overview of the Measles (Infectious Disease) pipeline landscape.

Measles is a highly infectious viral disease. The virus lives in the mucus of the nose and throat of people with this infection. Physical contact, coughing and sneezing can spread the infection. Symptoms of measles are high temperature, sore eyes (conjunctivitis), and a runny nose usually occur first, small white spots usually develop inside the mouth a day or so later, diarrhea and vomiting.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Measles - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Measles (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Measles (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Measles and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 1, 1, 4, 4 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 2, 1 and 1 molecules, respectively.

Measles (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Measles (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Measles (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Measles (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Measles (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Measles (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Measles (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Measles (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Measles - Overview
Measles - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Measles - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Measles - Companies Involved in Therapeutics Development
Amogen Pharma Pvt Ltd
Beijing Minhai Biotechnology Co Ltd
Biological E Ltd
Daiichi Sankyo Co Ltd
Enesi Pharma Ltd
Indian Immunologicals Ltd
Micron Biomedical Inc
Panacea Biotec Ltd
Seagull BioSolutions Pvt Ltd
Sinovac Biotech Ltd
Vaxxas Inc
VBI Vaccines Inc
Zydus Lifesciences Ltd
Measles - Drug Profiles
(measles + mumps + rubella + varicella) vaccine - Drug Profile
Product Description
Mechanism Of Action
(measles + mumps + rubella + varicella) vaccine - Drug Profile
Product Description
Mechanism Of Action
(measles + mumps + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
(measles + mumps + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
(measles + mumps + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
(measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
BK-1601 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ERDRP-0519 - Drug Profile
Product Description
Mechanism Of Action
measles vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
measles vaccine - Drug Profile
Product Description
Mechanism Of Action
measles vaccine - Drug Profile
Product Description
Mechanism Of Action
SBPL-0500 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Measles - Drug Profile
Product Description
Mechanism Of Action
VN-0102 - Drug Profile
Product Description
Mechanism Of Action
Measles - Dormant Projects
Measles - Product Development Milestones
Featured News & Press Releases
May 05, 2021: Enesi Pharma achieves key milestone in development of thermostable solid-dose live vaccines against measles and rubella
Mar 18, 2020: Vaxxas awarded US$5 million grant for clinical study of measles and rubella vaccination
Nov 30, 2019: Vaxxas was awarded research and development fund of USD 4,997,693 from Bill & Melinda Gates Foundation
Nov 30, 2016: Vaxxas was awarded research and development fund of USD 4,479,552 from Bill & Melinda Gates Foundation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Measles, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Measles - Pipeline by Amogen Pharma Pvt Ltd, 2022
Measles - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022
Measles - Pipeline by Biological E Ltd, 2022
Measles - Pipeline by Daiichi Sankyo Co Ltd, 2022
Measles - Pipeline by Enesi Pharma Ltd, 2022
Measles - Pipeline by Indian Immunologicals Ltd, 2022
Measles - Pipeline by Micron Biomedical Inc, 2022
Measles - Pipeline by Panacea Biotec Ltd, 2022
Measles - Pipeline by Seagull BioSolutions Pvt Ltd, 2022
Measles - Pipeline by Sinovac Biotech Ltd, 2022
Measles - Pipeline by Vaxxas Inc, 2022
Measles - Pipeline by VBI Vaccines Inc, 2022
Measles - Pipeline by Zydus Lifesciences Ltd, 2022
Measles - Dormant Projects, 2022

LIST OF FIGURES

Number of Products under Development for Measles, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022


More Publications